Current pharmacologic treatment for orthostatic hypotension
|
|
- Andrea McDonald
- 6 years ago
- Views:
Transcription
1 Clin Auton Res (2008) 18[Suppl 1]:14 18 DOI /s ARTICLE Roy Freeman Current pharmacologic treatment for orthostatic hypotension Received: 18 June 2007 Accepted: 5 July 2007 R. Freeman, MD (&) Dept. of Neurology Harvard Medical School Center for Autonomic and Peripheral Nerve Disorders Beth Israel Deaconess Medical Center One Deaconess Road Boston (MA) 02215, USA Tel.: / Fax: / rfreeman@bidmc.harvard.edu j Abstract Orthostatic hypotension is treated effectively with the combined use of non-pharmacological and pharmacological interventions. Patients should be counseled as to the nature of the underlying disorder and reversible causes of orthostatic hypotension should be removed. Should symptoms persist, pharmacological treatment is implemented. First line pharmacotherapeutic interventions include volume repletion in combination with alpha-adrenoreceptor agonists. If unsuccessful there are several supplementary agents with different mechanisms of action that may provide an additive effect. j Key words orthostatic hypotension Æ syncope Æ autonomic failure Æ sympathetic nervous system CAR 1003 Introduction Orthostatic hypotension is the most incapacitating symptom of autonomic failure. Fortunately, with the help of non-pharmacological and pharmacological interventions, most patients quality of life can be improved substantially. The therapeutic interventions to treat patients with orthostatic hypotension should be implemented in stages and depend, in large part, on the severity of symptoms. Some patients may be markedly improved by education, counseling, removal of hypotensive medications and other nonpharmacological interventions, while more severely afflicted patients require pharmacological interventions [9]. j Non-pharmacological measures Patient education is the cornerstone of the management of orthostatic hypotension. Throughout the day, patients are subject to a number of orthostatic demands for which there are simple but effective countermeasures. The time spent with patients emphasizing these practical management principles is of inestimable value. These include moving from a supine to standing position in gradual stages; avoiding orthostatic stress in the morning when orthostatic tolerance is lowest [24]; minimizing straining and isometric exercise; should be discouraged; and avoiding deconditioning. Frequent small meals are preferable as food ingestion often exacerbates orthostatic hypotension [19, 32]. Physical counter-maneuvers such as leg-crossing and squatting may be used to facilitate cerebral perfusion by increasing central blood volume and cardiac filling pressures [39]. The use of custom fitted elastic stockings may also be used to provide a graded pressure to the lower extremity and abdomen. Medications such as diuretics, anti-hypertensive agents, anti-anginal agents, anti-depressants and alpha adrenoreceptor antagonists should be tapered as these can cause or exacerbate orthostatic hypotension.
2 15 Table 1 Volume expansion Fluid and sodium chloride 9-a-Fluorohydrocortisone Vasopressin analogs Acute water ingestion j Volume expansion Administration of fluid and sodium chloride Plasma volume expansion is essential to improve orthostatic tolerance. The high nocturnal blood pressure causes a pressure natriuresis and results in nocturnal volume and sodium chloride depletion. Several measures are available for maintaining and repleting plasma volume (See Table 1). Patients should have a daily dietary intake of least 10 g (185 mmol) of sodium per day accompanied by an increase in fluid intake of l (in adults) per day. An early morning body weight gain of about 1 2 kg usually implies adequate extra-cellular fluid volume expansion [38]. Ingestion of approximately 500 cc of tap water elicits a marked pressor response and improvement in symptoms in patients with autonomic failure. The pressor response, a systolic blood pressure increase of over 30 mmhg in some patients, is evident within 5 minutes after the water ingestion [14]. 9-a-Fluorohydrocortisone 9-a-Fluorohydrocortisone (fludrocortisone acetate), a synthetic mineralocorticoid, may be used if patient are unable to increase plasma volume effectively with fluid and salt [3, 11, 18]. This agent has a long duration of action and is well-tolerated by most patients. Fludrocortisone increases the blood volume and enhances the sensitivity of blood vessels to circulating catecholamines [7, 11]. Other potential modes of action include enhancing norepinephrine release from sympathetic neurons and increasing vascular fluid content [34]. Treatment is initiated with a 0.1 mg tablet and can be increased to mg daily [38]. Treatment may unfortunately be limited by supine hypertension due to an increase in the peripheral vascular resistance [4]. Other side effects include ankle edema, hypokalemia, headache and rarely congestive heart failure. Potassium supplementation is usually required, particularly when higher doses are used. Vasopressin analogs The vasopressin analogs may be used to supplement volume expansion. Arginine-vasopressin has a circadian rhythm that peaks during the night. Thus, the increase in nocturnal urinary excretion in patients Table 2 Sympathomimetic agonists Midodrine Ephedrine Pseudoephedrine Methylphenidate Dextroamphetamine with autonomic failure, which is in part due to the increase in supine blood pressures, is also due to loss of vasopressin neurons in the suprachiasmatic nucleus of the hypothalamus and the ensuing loss of the normal AVP circadian rhythm [27]. The potent, synthetic vasopressin analog desmopressin acetate (DDAVP) acts on the V2 receptors in the collecting ducts of the renal tubules and prevents nocturia, weight loss and reduces the morning postural fall in blood pressure. DDAVP is usually administered as a nasal spray (5 40 lg) or orally ( lg). Adverse events include water intoxication and hyponatremia [21]. Low doses of intranasal desmopressin (5 lg) may be sufficient to attenuate the nocturnal diuresis without placing the patient at risk for hyponatremia [33]. j Sympathomimetic agents The administration of sympathomimetic agents is central to the management of patients with cardiovascular autonomic failure. Thus, if symptoms of orthostatic intolerance persist once intravascular volume is replenished the direct or indirect adrenergic agonists and antagonists should be administered (See Table 2). The pressor response of these agents is due to the reduction in venous capacity and the constriction of the resistance vessels. The available a 1 -adrenoreceptor agonists include those with direct and indirect effects (ephedrine, pseudoephedrine), those with direct effects (midodrine and phenylephrine) and those with only indirect effects (methylphenidate and dextroamphetamine sulphate). The peripheral selective direct, a 1 -adrenoreceptor agonist midodrine is the only agent approved by the FDA for the treatment of orthostatic hypotension [20]. Its efficacy has been demonstrated in doubleblind placebo controlled studies [15, 20, 42]. Midodrine, the prodrug is activated to desglymidodrine, the active a-adrenoreceptor agonist. Midodrine has an elimination half life of 0.5 hours and is undetectable in plasma 2 hours after an oral dose. The agent undergoes enzymatic hydrolysis (deglycination) in the systemic circulation to form the active agent, desglymidodrine. Desglymidodrine is 15 times more potent than midodrine and is primarily responsible for the therapeutic effect. The elimination half-life of
3 16 Table 3 Supplementary therapy Acetylcholinesterase inhibition Caffeine Erythropoietin b-blockers Clonidine Yohimbine desglymidodrine is 2 4 hours. Desglymidodrine is predominantly excreted by the kidneys. Patient sensitivity to this agent varies and the dose should be titrated from 2.5 mg to 10 mg three times a day. The peak effect of this agent occurs 1 hour after ingestion [42]. Potential side effects of midodrine include pilomotor reactions, pruritus, supine hypertension, gastrointestinal complaints, and urinary retention. Central nervous system side-effects occur infrequently. The mixed a-adrenoreceptor agonists which act directly on the a-adrenoreceptor and release norepinephrine from the post-ganglionic sympathetic neuron include ephedrine, pseudoephedrine. There are structural, pharmacological and therapeutic differences between these agents and midodrine. Ephedrine is an agonist of a, b 1 and b 2 receptors. The b 2 vasodilatory effects may attenuate the pressor effect of this drug. Pseudoephedrine, a stereoisomer of ephedrine has similar pharmacological and therapeutic properties [13]. Typical doses of the agents are ephedrine: mg three times a day; and pseudoephedrine: mg three times a day. Because the effectiveness of these agents is at least in part due to the release of norepinephrine from the post-ganglionic neuron, these medications are in theory most likely to benefit patients with partial or incomplete lesions [1, 6, 10]. The indirect agonists, methylphenidate and dextroamphetamine, that release norepinephrine from post-ganglionic neurons are infrequently used to treat orthostatic hypotension. In a small head-to-head trial midodrine (mean dose 8.4 mg tid) improved standing blood pressure and orthostatic tolerance more than ephedrine (22.3 mg tid) [8]. In another trial, phenylpropanolamine (12.5 mg) and yohimbine (5.4 mg) produced equivalent increases in standing systolic blood pressure while methylphenidate failed to increase standing systolic blood pressure significantly [13]. The use of the sympathomimetic agents (with the possible exception of midodrine) may be complicated by tachyphylaxis, although efficacy may be regained after a short drug holiday. The central sympathomimetic side-effects such anxiety, tremulousness and tachycardia that invariably accompany the use of these agents are frequently intolerable to patients. Midodrine, which does not cross the blood brain barrier in significant amounts, does not have these central sympathomimetic side-effects. There is evidence that phenylpropanolamine increases the risk of hemorrhagic stroke in women [16] and the FDA has suggested that phenylpropanolamine be removed from all drug products. Severe hypertension is an important adverse-effect of all sympathomimetic agents. Patients should not take these medications for 4 hours prior to recumbency. Patients taking midodrine report piloerection, pruritus and tingling. These are most likely peripheral sympathomimetic effects of the drug. j Supplementary therapy There are rare patients who do not respond to first line interventions and require additional agents to treat their symptoms. These supplementary agents may provide an additive therapeutic effect to the firstline therapies (see Table 3). Acetylcholinesterase inhibition The acetylcholinesterase inhibitor, pyridostigmine, (60 mg) administered orally increased head-up tilt blood pressure and reduced orthostatic hypotension in patients with neurogenic orthostatic hypotension. The associated increase in supine blood pressure may not be as great as that seen with other pressors. Twenty percent of patients report cholinergic sideeffects. The rationale for the use of this agent is that inhibition of acetylcholinesterase enhance sympathetic ganglionic neurotransmission and that the effect is maximal while upright, when sympathetic nerve traffic is greatest [35]. Caffeine The methylxanthine caffeine has a well-established, although modest, pressor effect that is in part due to blockade of vasodilating adenosine receptors. The pressor effect is subject to tachyphylaxis. Typical caffeine doses are mg three times a day, either as tablets or caffeinated beverages (one cup of coffee contains approximately 85 mg of caffeine and one cup tea contains 50 mg of caffeine) [25]. Erythropoietin Erythropoietin increases standing blood pressure and improves orthostatic tolerance in patients with orthostatic hypotension [12, 28]. This agent corrects the normochromic normocytic anemia that frequently accompanies autonomic failure [2, 41] and diabetic autonomic neuropathy [40].
4 17 Recombinant human erythropoietin, erythropoietin alpha, is administered subcutaneously or intravenously at doses between 25 and 75 U per kg three times a week until a hematocrit that approaches normal is attained. Lower maintenance doses (approximately 25 U per kg three times a week) may then be used. Iron supplementation is usually required, particularly during the period when the hematocrit is increasing. Erythropoietin increases red cell mass and central blood volume although the precise mechanism of action of this agent is not resolved. There is evidence that the effect of erythropoietin is related to vascular tone regulation mediated by the interaction between hemoglobin and the vasodilator nitric oxide [29]. Supine hypertension may accompany the use of erythropoietin [12, 28]. b-blockers Nonselective b-blockers, particularly those with intrinsic sympathomimetic activity such as pindolol and xamoterol, may have a limited place in the treatment of orthostatic hypotension despite the wellacknowledged negative chronotropy and inotropy associated with these medications [5, 22, 23, 37]. The suggested mechanism of action of these medications is the blockade of vasodilating b-2 receptors allowing unopposed a-adrenoreceptor mediated vasoconstrictor effects to dominate. The pressor effect of these agents has not been demonstrated consistently in clinical trials [17]. Clonidine Clonidine is an a2 agonist that usually produces a central, sympatholytic effect and a consequent decrease in blood pressure. In patients with autonomic failure, who have little central sympathetic efferent activity, the effect of this agent on post synaptic a 2 adrenoreceptors may predominate. The use of clonidine ( mg per day) could therefore result in an increase in venous return without a significant increase in peripheral vascular resistance although mechanism of action is still not clearly defined [36]. The use of this agent, at least theoretically, is limited to patients with severe central autonomic dysfunction in whom there is no ostensible effect of further sympatholysis and the peripheral effect may dominate [30, 31]. Clonidine should be used cautiously as exacerbation of hypotension may occur. Side-effects include somnolence, xerostomia and constipation. Yohimbine Yohimbine is a centrally and peripherally active selective a 2 adrenoreceptor antagonist that increases sympathetic nervous system efferent output by antagonizing central or presynaptic a 2 -adrenoreceptors or both. This agent, theoretically, should be more effective in patients that have some residual sympathetic nervous system output, although this has not always been borne out in clinical studies. Side effects of yohimbine include anxiety, tremor, palpitations, diarrhea and supine hypertension [13, 26]. Conclusion With the help of non-pharmacological and pharmacological interventions, most patients quality of life can be improved substantially. Treatment should be initiated in stages. First, patients should be counseled as to the nature of the underlying disorder and reversible causes of orthostatic hypotension should be removed. If symptoms persist, pharmacological treatment is implemented. Many patients will be adequately treated by education, counseling, removal of hypotensive medications and other non-pharmacological interventions while more severely afflicted patients require pharmacological interventions. j Disclosure Dr. Freeman has served as a consultant for Chelsea Therapeutics. References 1. Biaggioni I, Onrot J, Stewart CK, Robertson D (1987) The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA 258: Biaggioni I, Robertson D, Krantz S, Jones M, Haile V (1994) The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 121: Campbell IW, Ewing DJ, Clarke BF (1975) 9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes 24: Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D (1979) Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 301: Cleophas TJ, Grabowsky I, Niemeyer MG, Makel WM, van der Wall EE (2002) Paradoxical pressor effects of beta-blockers in standing elderly patients with mild hypertension: a beneficial side effect. Circulation 105: Davies B, Bannister R, Sever P (1978) Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure. Limitations and hazards. Lancet 1:
5 18 7. Davies IB, Bannister RG, Sever PS, Wilcox CS (1978) Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents [proceedings]. Br J Clin Pharmacol 6:444P 445P 8. Fouad-Tarazi FM, Okabe M, Goren H (1995) Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med 99: Freeman R (2003) Treatment of orthostatic hypotension Semin Neurol 23: Ghrist DG, Brown GE (1928) Postural hypertension with syncope: its successful treatment with ephedrine. Am J Med Sci 175: Hickler RB, Thompson GR, Fox LM, Hamlin JT (1959) Successful treatment of orthostatic hypotension with 9-alpha-fluorohydrocortisone. N Engl J Med 261: Hoeldtke RD, Streeten DHP, Streeten DH (1993) Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 329: Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D (1998) Contrasting actions of pressor agents in severe autonomic failure. Am J Med 105: Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, Diedrich A, Robertson RM, Biaggioni I, Robertson D (2000) The pressor response to water drinking in humans: a sympathetic reflex? Circulation 101: Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J (1988) Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 38: Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI (2000) Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343: Leslie PJ, Thompson C, Clarke BF, Ewing DJ (1991) A double-blind crossover study of oral xamoterol in postural hypotension due to diabetic autonomic neuropathy. Clin Auton Res 1: van Lieshout JJ, ten Harkel AD, Wieling W. (2000) Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res 10: Lipsitz LA, Ryan SM, Parker JA, Freeman R, Wei JY, Goldberger AL. (1993) Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension. Circulation 87: Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, doubleblind multicenter study. Midodrine Study Group. JAMA 277: Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R (1986) The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J Clin Res 293: Mehlsen J, Trap-Jensen J (1986) Xamoterol, a new selective beta-1- adrenoceptor partial agonist, in the treatment of postural hypotension. Acta Med Scand 219: Obara A, Yamashita H, Onodera S, Yahara O, Honda H, Hasebe N (1992) Effect of xamoterol in Shy-Drager syndrome. Circulation 85: Omboni S, Smit AA, van Lieshout JJ, Settels JJ, Langewouters GJ, Wieling W (2001) Mechanisms underlying the impairment in orthostatic tolerance after nocturnal recumbency in patients with autonomic failure. Clin Sci (Lond) 101: Onrot J, Goldberg MR, Biaggioni I, Hollister AS, Kingaid D, Robertson D (1985) Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med 313: Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D (1987) Oral yohimbine in human autonomic failure. Neurology 37: Ozawa T, Tanaka H, Nakano R, Sato M, Inuzuka T, Soma Y, Yoshimura N, Fukuhara N, Tsuji S (1999) Nocturnal decrease in vasopressin secretion into plasma in patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 67: Perera R, Isola L, Kaufmann H (1995) Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 5: Rao SV, Stamler JS (2002) Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin Auton Res 12: Robertson D, Goldberg MR, Hollister AS, Wade D, Robertson RM (1983) Clonidine raises blood pressure in idiopathic orthostatic hypotension. Am J Med 74: Robertson D, Goldberg MR, Tung CS, Hollister AS, Robertson RM. (1986) Use of alpha 2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. J Clin Invest 78: Robertson D, Wade D, Robertson RM (1981) Postprandial alterations in cardiovascular hemodynamics in autonomic dysfunction states. Am J Cardiol 48: Sakakibara R, Matsuda S, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2003) The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 13: Schatz IJ, Miller MJ, Frame B (1976) Corticosteroids in the management of orthostatic hypotension. Cardiology 61(suppl 1): Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA (2003) Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 74: Victor RG, Talman WT (2002) Comparative effects of clonidine and dihydroergotamine on venomotor tone and orthostatic tolerance in patients with severe hypoadrenergic orthostatic hypotension. Am J Med 112: West JN, Stallard TJ, Dimmitt SB, Smith SA, Williams A, Littler WA (1990) Xamoterol in the treatment of orthostatic hypotension associated with multiple system atrophy (Shy- Drager syndrome). Q J Med 74: Wieling W, van Lieshout JJ, Hainsworth R (2002) Extracellular fluid volume expansion in patients with posturally related syncope. Clin Auton Res 12: Wieling W, van Lieshout JJ, van Leeuwen AM (1993) Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin Auton Res 3: Winkler AS, Landau S, Watkins P, Chaudhuri KR (2002) Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. Clin Auton Res 12: Winkler AS, Marsden J, Parton M, Watkins PJ, Chaudhuri KR (2001) Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord 16: Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA (1998) A doubleblind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 51:
:{ic0fp'16. Geriatric Medicine: Blood Pressure Monitoring in the Elderly. Terrie Ginsberg, DO, FACOI
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Blood Pressure Monitoring in the Elderly Terrie Ginsberg, DO, FACOI Blood Pressure Management in the Elderly Terrie B.
More informationPOSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) IT S NOT THAT SIMPLE
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) IT S NOT THAT SIMPLE POTS Irritable heart syndrome. Soldier s heart. Effort syndrome. Vasoregulatory asthenia. Neurocirculatory asthenia. Anxiety neurosis.
More informationNorthera (droxidopa)
Northera (droxidopa) Policy Number: 5.01.657 Last Review: 07/2018 Origination: 07/2018 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Northera
More informationI ngestion of water increases seated blood pressure (BP) in
1737 PAPER The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure T M Young, C J Mathias... See end of
More informationNORTHERA (droxidopa) oral capsule
NORTHERA (droxidopa) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationEvidence-based treatment of neurogenic orthostatic hypotension and related symptoms
J Neural Transm (2017) 124:1567 1605 DOI 10.1007/s00702-017-1791-y HIGH IMPACT REVIEW IN NEUROSCIENCE, NEUROLOGY OR PSYCHIATRY - REVIEW ARTICLE Evidence-based treatment of neurogenic orthostatic hypotension
More informationContempo GIMSI Cosa cambia alla luce della letteratura in tema di terapia farmacologica
Contempo GIMSI 2015-2017 Cosa cambia alla luce della letteratura in tema di terapia farmacologica Dott.ssa Diana Solari Centro Aritmologico e Sincope Unit, Lavagna www.gimsi.it POST 2 (Prevention of Syncope
More informationSYNCOPE. Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope
SYNCOPE Sanjay P. Singh, MD Chairman & Professor, Department of Neurology. Syncope Syncope is a clinical syndrome characterized by transient loss of consciousness (TLOC) and postural tone that is most
More informationOrthostatic Hypotension
Orthostatic Hypotension http://suntechmed.web4.hubspot.com/portals/41365/images/bloodpressuredoctor.jpg Orthostatic (postural) hypotension is an excessive fall in BP when an upright position is assumed.
More informationNeurogenic orthostatic hypotension: the very basics
Clin Auton Res (2017) 27:39 43 DOI 10.1007/s10286-017-0437-3 EDITORIAL Neurogenic orthostatic hypotension: the very basics Horacio Kaufmann 1 Jose-Alberto Palma 1 Received: 7 June 2017 / Accepted: 8 June
More informationHow To Manage Autonomic Symptoms in Multiple System Atrophy. Amanda C. Peltier, MD MS Neurology
How To Manage Autonomic Symptoms in Multiple System Atrophy Amanda C. Peltier, MD MS Neurology Disclosures NIH Autonomic Rare Diseases Consortium Checking your blood pressure several times a day is helpful
More informationDesmopressin In The Treatment of Postural Orthostatic Tachycardia
The Journal of Innovations in Cardiac Rhythm Management, 6 (2015), 2222 2226 DOI: 10.19102/icrm. 2015.061202 PHARMACOLOGICAL THERAPY RESEARCH ARTICLE Desmopressin In The Treatment of Postural Orthostatic
More informationPyridostigmine in the Treatment of Postural Orthostatic Tachycardia: A Single-Center Experience
Pyridostigmine in the Treatment of Postural Orthostatic Tachycardia: A Single-Center Experience KHALIL KANJWAL, M.D.,* BEVERLY KARABIN, PH.D.,* MUJEEB SHEIKH, M.D.,* LAWRENCE ELMER, M.D., PH.D., YOUSUF
More informationExercise Training for PoTS and Syncope
B 140 120 100 80 60 40 20 0 Blood Pressure (mm Hg) Blood Pressure Heart Rate 60 degree Head Up Tilt Time 140 120 100 80 60 40 20 0 Heart Rate (beats.min -1 ) Exercise Training for PoTS and Syncope C Blood
More informationSYMPATHETIC STRESSORS AND SYMPATHETIC FAILURES
SYMPATHETIC STRESSORS AND SYMPATHETIC FAILURES Any discussion of sympathetic involvement in circulation, and vasodilation, and vasoconstriction requires an understanding that there is no such thing as
More informationFaculty Disclosure. Sanjay P. Singh, MD, FAAN. Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion
Faculty Disclosure Sanjay P. Singh, MD, FAAN Dr. Singh has listed an affiliation with: Consultant Sun Pharma Speaker s Bureau Lundbeck, Sunovion however, no conflict of interest exists for this conference.
More informationGanglionic Blockers. Ganglion- blocking agents competitively block the action of
Ganglionic Blockers Ganglion- blocking agents competitively block the action of acetylcholine and similar agonists at nicotinic (Nn) receptors of both parasympathetic and sympathetic autonomic ganglia.
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationTreatment of Postural Orthostatic Tachycardia Syndrome and Inappropriate Sinus Tachycardia
Treatment of Postural Orthostatic Tachycardia Syndrome and Inappropriate Sinus Tachycardia M. Yousuf Kanjwal, MD*, Daniel J. Kosinski, MD, and Blair P. Grubb, MD Address *Medical College of Ohio, Room
More informationJune 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE
June 8, 2018, London UK TREATMENT OF VASOVAGAL SYNCOPE Where to go for help Syncope: HRS Definition Syncope is defined as: a transient loss of consciousness, associated with an inability to maintain postural
More informationBeta 1 Beta blockers A - Propranolol,
Pharma Lecture 3 Beta blockers that we are most interested in are the ones that target Beta 1 receptors. Beta blockers A - Propranolol, it s a non-selective competitive antagonist of beta 1 and beta 2
More informationdroxidopa (Northera )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationNIH Public Access Author Manuscript Lancet Neurol. Author manuscript; available in PMC 2009 January 16.
NIH Public Access Author Manuscript Published in final edited form as: Lancet Neurol. 2008 May ; 7(5): 451 458. doi:10.1016/s1474-4422(08)70088-7. Update on Management of Neurogenic Orthostatic Hypotension
More informationVasoactive Medications. Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis
Vasoactive Medications Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis Objectives List components of physiology involved in blood pressure Review terminology related
More informationWednesday September 20 th CMT Regional Study Day. Dr Colin Mason, Consultant DME, Addenbrooke s Hospital
Wednesday September 20 th CMT Regional Study Day Dr Colin Mason, Consultant DME, Addenbrooke s Hospital Develop a structured approach to a patient presenting with a fall Risk stratify who can go home and
More informationFindings from the 2015 HRS Expert Consensus Document on Postural Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST)
Findings from the 2015 HRS Expert Consensus Document on Postural Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST) Ahmad Hersi, MBBS, MSc, FRCPC Professor of Cardiac Sciences Consultant
More informationDiagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study
Diagnosing and Treating Neurogenic Orthostatic Hypotension: A Case Study Learning Objectives: Illustrate how to accurately diagnose noh Employ scales and questionnaires in combination with cardiovascular
More informationTitrating Critical Care Medications
Titrating Critical Care Medications Chad Johnson, MSN (NED), RN, CNCC(C), CNS-cc Clinical Nurse Specialist: Critical Care and Neurosurgical Services E-mail: johnsoc@tbh.net Copyright 2017 1 Learning Objectives
More informationOrthostatic Hypotension in the Elderly: Diagnosis and Treatment
The American Journal of Medicine (2007) 120, 841-847 OFFICE MANAGEMENT: GERIATRICS Michael W. Rich, MD, Speciality Editor Orthostatic Hypotension in the Elderly: Diagnosis and Treatment Vishal Gupta, MD,
More informationL-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension
Clin Auton Res (2008) 18[Suppl 1]:19 24 DOI 10.1007/s10286-007-1002-2 ARTICLE Horacio Kaufmann L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension The US experience
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationNOCTIVA (desmopressin acetate) nasal spray
NOCTIVA (desmopressin acetate) nasal spray Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationThe mechanisms that maintain water and electrolyte homeostasis
The Pressor Response to Water Drinking in Humans A Sympathetic Reflex? Jens Jordan, MD; John R. Shannon, MD; Bonnie K. Black, BSN; Yasmine Ali, BS; Mary Farley; Fernando Costa, MD; Andre Diedrich, MD;
More informationAUTONOMIC DRUGS: ADRENOCEPTOR AGONISTS AND SYMPATHOMIMETICS. Lecture 4
AUTONOMIC DRUGS: ADRENOCEPTOR AGONISTS AND SYMPATHOMIMETICS Lecture 4 Introduction (review) 5 key features of neurotransmitter function, which can be targets for pharmacotherapy Synthesis Storage Release
More informationThe adrenergic drugs affect receptors that are stimulated by norepinephrine or epinephrine. Some adrenergic drugs act directly on the adrenergic
Adrenergic drugs The adrenergic drugs affect receptors that are stimulated by norepinephrine or epinephrine. Some adrenergic drugs act directly on the adrenergic receptor (adrenoceptor) by activating it
More informationHRV in Diabetes and Other Disorders
HRV in Diabetes and Other Disorders Roy Freeman, MD Center for Autonomic and Peripheral Nerve Disorders Beth Israel Deaconess Medical Center Harvard Medical School Control Propranolol Atropine Wheeler
More informationHypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to
Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to 90 mmhg. These pressures are called Normal blood pressure
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationINTRODUCTION POTS is: Poorly understood Rarely considered SIGNIFICANT morbidity Appropriate initial diagnosis & care will expedite management of POTS
Learning objectives At the end of this presentation the learner should: Define POTS & identify the various etiologies of POTS Be able to differentiate POTS from other causes of orthostatic intolerance
More information1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias
1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationAutonomic Nervous System (ANS) وحدة اليوزبكي Department of Pharmacology- College of Medicine- University of Mosul
Autonomic Nervous System (ANS) د. م. أ. وحدة اليوزبكي Department of Pharmacology- College of Medicine- University of Mosul Sympathetic (Adrenergic) nervous system 3 Objectives At end of this lecture, the
More informationMETOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets
METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets COMPOSITION Each film-coated tablet of Metotrust XL-25 contains: Metoprolol Succinate USP 23.75 mg equivalent to Metoprolol Tartrate 25
More informationRecognition and Management of Orthostatic Hypotension in Primary Care
Recognition and Management of Orthostatic Hypotension in Primary Care Jennifer Jones, MD; Louis Kuritzky, MD CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Classify patients by type of orthostatic hypotension
More informationPharmacology - Problem Drill 11: Vasoactive Agents
Pharmacology - Problem Drill 11: Vasoactive Agents Question No. 1 of 10 1. Vascular smooth muscle contraction is triggered by a rise in. Question #01 (A) Luminal calcium (B) Extracellular calcium (C) Intracellular
More informationNOCTIVA (desmopressin acetate) nasal spray
NOCTIVA (desmopressin acetate) nasal spray Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationDr. David Robertson Elton Yates Professor of Autonomic Disorders Professor of Medicine, Pharmacology and Neurology Vanderbilt University April 2007
Dr. David Robertson Elton Yates Professor of Autonomic Disorders Professor of Medicine, Pharmacology and Neurology Vanderbilt University April 2007 Pathophysiology and Diagnosis of Orthostatic Hypotension
More informationNeurogenic orthostatic hypotension (NOH) results from
Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension Horacio Kaufmann, MD; Daniela Saadia, MD; Andrei Voustianiouk, PhD; David S. Goldstein, MD, PhD; Courtney Holmes, CMT; Melvin D. Yahr,
More informationProf dr Aleksandar Raskovic DIRECT VASODILATORS
Prof dr Aleksandar Raskovic DIRECT VASODILATORS Direct vasodilators Minoxidil (one of the most powerful peripheral arterial dilators) Opening of KATP channels, efflux of K, lose of Ca and smooth muscle
More informationNIH Public Access Author Manuscript Neurology. Author manuscript; available in PMC 2009 February 10.
NIH Public Access Author Manuscript Published in final edited form as: Neurology. 2008 May 13; 70(20): 1926 1932. doi:10.1212/01.wnl.0000312280.44805.5d. Autonomic Ganglia: Target and Novel Therapeutic
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each ml solution for injection contains phenylephrine hydrochloride corresponding to 0.1 mg phenylephrine.
1. NAME OF THE MEDICINAL PRODUCT Fenylefrin Abcur 0.05 mg/ml, solution for injection Fenylefrin Abcur 0.1 mg/ml, solution for injection SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE
More informationPostural Orthostatic Tachycardia Syndrome:
Postural Orthostatic Tachycardia Syndrome: A Case Presentation Interesting Cases from the Annals of Women s Heart Care I have no financial relationships or commercial interests to disclose that are relevant
More informationPHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker
PACKAGE INSERT Pr PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker ACTIONS AND CLINICAL PHARMACOLOGY Phentolamine produces an alpha-adrenergic
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 3 Pharmacology of the Autonomic Nervous System Multimedia Directory Slide 19 Slide 37 Slide 38 Slide 39 Slide 40 Slide 41 Slide 42 Slide 43
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationSystemic Pharmacology Lecture 7: Neuropharmacology
Systemic Pharmacology Lecture 7: Neuropharmacology Drugs act on Sympathetic NS (adrenergic system) Adrenergic Drugs (Sympathomimetics), adrenergic agonists, or alpha- and beta-adrenergic agonists Antiadrenergic
More informationExercise hemodynamics in Parkinson s Disease and autonomic dysfunction
Exercise hemodynamics in Parkinson s Disease and autonomic dysfunction David A. Low 1,2,3*, Ekawat Vichayanrat 2,3, Valeria Iodice 2,3 and Christopher J. Mathias 2,3 1 Research Institute of Sport and Exercise
More informationSystemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept
Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept Continents 1- introduction 2- classification/definition 3- classification/etiology 4-etiology in both categories 5- complications
More informationthe study to patients evaluated clinically by 2 of the authors (P.S., P.A.L.). Symptoms of orthostatic intolerance, aggravating factors, antecedent il
ORIGINAL ARTICLE POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME Postural Orthostatic Tachycardia Syndrome: The Mayo Clinic Experience MARK J. THIEBEN, MD; PAOLA SANDRONI, MD, PHD; DAVID M. SLETTEN; LISA M.
More informationBIMM118. Autonomic Nervous System
Autonomic Nervous System Autonomic Nervous System Ganglia close to the innervated organs Myelinated axons Ganglia close to the spinal column Preganglionic axons are myelinated; postganglionic axons are
More informationUse of Methylphenidate in the Treatment of Patients Suffering From Refractory Postural Tachycardia Syndrome
American Journal of Therapeutics 0, 000 000 (2010) Use of Methylphenidate in the Treatment of Patients Suffering From Refractory Postural Tachycardia Syndrome Khalil Kanjwal, MD, 1 Bilal Saeed, MD, 2 Beverly
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationTreatments for Dysautonomias
Treatments for Dysautonomias Successful treatment of dysautonomias usually requires an individualized program, which can change over time. You should understand that since the underlying mechanisms often
More informationL-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension
Clin Auton Res (8) 8[Suppl ]:5 9 DOI.7/s86-7-5-z ARTICLE Christopher J. Mathias L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension The European experience Received: 5 October
More informationThe postural tachycardia syndrome (POTS) is characterized
Sympathetic Nerve Activity in Response to Hypotensive Stress in the Postural Tachycardia Syndrome Istvan Bonyhay, MD, PhD; Roy Freeman, MD Background Increased central sympathetic activity and/or deficient
More informationADRENERGIC AGONISTS. Course: Integrated Therapeutics 1. Lecturer: Dr. E. Konorev. Date: September 16, Materials on: Exam #2
ADRENERGIC AGONISTS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: September 16, 2010 Materials on: Exam #2 Required reading: Katzung, Chapter 9 1 ADRENERGIC NEUROTRANSMISSION Pre-Synaptic
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationKnowledge of the clinical disorders due to autonomic
AJH 2006; 19:319 326 REVIEW Autonomic Response Orthostatic Hypotension Due to Autonomic Disorders in the Hypertension Clinic George A. Mansoor Hypertension specialists are consulted regarding orthostatic
More informationAutonomic Nervous System
Autonomic Nervous System Keri Muma Bio 6 Organization of the Nervous System Efferent Division Somatic Nervous System Voluntary control Effector = skeletal muscles Muscles must be excited by a motor neuron
More informationAdrenergic Agonists 1
Adrenergic Agonists 1 THE ADRENERGIC NEURON Adrenergic neurons release norepinephrine as the primary neurotransmitter. These neurons are found in the central nervous system (CNS) and also in the sympathetic
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationSyncope Guidelines: What s New?
Syncope Guidelines: What s New? Dr. Samuel Asirvatham Professor of Medicine and Pediatrics Mayo Clinic College of Medicine Medical Director, Electrophysiology Laboratory Program Director, EP Fellowship
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationDisclosures. Adult Postural Orthostatic Tachycardia Syndrome (POTS) Topics. Objectives. Definition/Terminology. Epidemiology 2/2/2017
Disclosures Adult Postural Orthostatic Tachycardia Syndrome (POTS) Nothing to disclose (no financial or pharmaceutical affiliations) All discussed pharmacologic treatments are off-label Juan J. Figueroa,
More informationWhat is Nocturia? What are the Consequences of Nocturia? 23/10/12. Dr. Tam Cheuk Kwan Consultant, Dept. of M&G Tuen Mun Hospital
Survival 23/10/12 Dr. Tam Cheuk Kwan Consultant, Dept. of M&G Tuen Mun Hospital What is Nocturia? Nocturia is the complaint that the individual has to wake at night one or more times to void. (ICS definition
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationPITTMed Cardiology. Pharmacology Modules. Learning Objectives. Site Contents. Fall 2018
PITTMed Cardiology Fall 2018 Site Contents Pharmacology Modules Please complete the following modules during the first week of class: Adrenergics Cholinergics Adrenergic Drugs in Cardiology Hypercalcemia
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationPostural Tachycardia Syndrome (POTS)
352 Clinical Review Editor: Stephen C. Hammill, M.D. Postural Tachycardia Syndrome (POTS) PHILLIP A. LOW, M.D., PAOLA SANDRONI, M.D., Ph.D., MICHAEL JOYNER, M.D., and WIN-KUANG SHEN, M.D. From the Department
More informationNIH Public Access Author Manuscript J Cardiovasc Electrophysiol. Author manuscript; available in PMC 2014 January 28.
NIH Public Access Author Manuscript Published in final edited form as: J Cardiovasc Electrophysiol. 2009 March ; 20(3): 352 358. doi:10.1111/j.1540-8167.2008.01407.x. Postural Tachycardia Syndrome (POTS)
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationHypovolemic Shock: Regulation of Blood Pressure
CARDIOVASCULAR PHYSIOLOGY 81 Case 15 Hypovolemic Shock: Regulation of Blood Pressure Mavis Byrne is a 78-year-old widow who was brought to the emergency room one evening by her sister. Early in the day,
More informationIntroduction. William Smith 1 Hong Wan. Patrick Martin 2,4
Clin Auton Res (2016) 26:269 277 DOI 10.1007/s10286-016-0363-9 RESEARCH ARTICLE Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled,
More information- Dr Alia Shatnawi. 1 P a g e
- 1 مها أبو عجمية - - - Dr Alia Shatnawi 1 P a g e A Skippable Intr0 Blood pressure normally decreases during the night. Absence of this phenomenon is called (nondipping) Wikipedia: Circadian rhythm....
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationOrthostatic Hypotension (Postural Hypotension)
Orthostatic Hypotension (Postural Hypotension) Authors: SCIRE Community Team Reviewed by: Darryl Caves, PT Last updated: April 9, 2018 Changes to blood pressure control after spinal cord injury (SCI) may
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationIncreased forearm vascular resistance after dopamine blockade
Br. J. clin. Pharnac. (1984), 17, 373-378 Increased forearm vascular resistance after dopamine blockade D. MANNERING, E.D. BENNE7T, N. MEHTA & F. KEMP Department of Medicine 1, St George's Hospital Medical
More informationORTHOSTATIC INTOLERANCE AN EXPRESSION OF AUTONOMIC DISFUNCTION IN PARKINSON S DISEASE
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2014 vol. 118, no. 1 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS ORTHOSTATIC INTOLERANCE AN EXPRESSION OF AUTONOMIC DISFUNCTION IN PARKINSON S DISEASE Emilia-Lidia
More informationNote: At the end of the instructions, you will find a table which must be filled in to complete the exercise.
Autonomic Nervous System Theoretical foundations and instructions for conducting practical exercises carried out during the course List of practical exercises 1. Deep (controlled) breath test 2. Cold pressor
More informationShared Care Guideline
Shared Care Guideline Midodrine for Orthostatic hypotension and neurocardiogenic syncope Executive Summary Update of Guideline following licencing of drug. The responsibility for initiating midodrine will
More informationIntroduction. Orthostatic hypotension. Overview
Autonomic neuropathy: treatment By Aziz I Shaibani MD (Dr. Shaibani of Baylor College of Medicine has no relevant financial relationships to disclose.) Duaa Jabari MD (Dr. Jabari of the Mississippi Medical
More informationAntihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment
Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit
More information1. At the venous end of a capillary, is the dominant force determining water movement. a. Pcap b. cap c. PIF d. IF e. [Na+]
P531: Exam 1 Sample Question Set #3 The first 9 questions are the relevant questions from the beginning of lecture each day. The remaining 16 questions cover material from the last week of lectures. 1.
More informationNOCTURIA WHAT S KEEPING YOU UP AT NIGHT? Frances Stewart RN,NCA
WHAT S KEEPING YOU UP AT NIGHT? Frances Stewart RN,NCA Objectives Be more knowledgeable in the diagnosis and treatment of nocturia Differentiate between urological causes of nocturia Select appropriate
More informationDiagnosis and Treatment of Syncope. Chang Gung Memorial Hospital, Chiayi Department of Pharmacy Serve Speaker: Yi-Shiou Chen Date:2013/11/27
Diagnosis and Treatment of Syncope Chang Gung Memorial Hospital, Chiayi Department of Pharmacy Serve Speaker: Yi-Shiou Chen Date:2013/11/27 Basic information Classification of Syncope Diagnosis Treatment
More informationAdrenoceptor Agonists & Sympathomimetic Drugs
Adrenoceptor Agonists & Sympathomimetic Drugs Alpha agonists Phenylephrine, methoxamine Clonidine, methylnorepinephrine Relative Receptor Affinities α 1 >α 2 >>>>> β α 2 > α 1 >>>>> β Mixed alpha and beta
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationWhat would be the response of the sympathetic system to this patient s decrease in arterial pressure?
CASE 51 A 62-year-old man undergoes surgery to correct a herniated disc in his spine. The patient is thought to have an uncomplicated surgery until he complains of extreme abdominal distention and pain
More information